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Ciprofloxacin is used in neonates with suspected or documented Gram-negative serious infections. Currently, its use is off-label
partly because of lack of pharmacokinetic studies. Within the FP7 EU project TINN (Treat Infection in NeoNates), our aim was
to evaluate the population pharmacokinetics of ciprofloxacin in neonates and young infants <3 months of age and define the
appropriate dose in order to optimize ciprofloxacin treatment in this vulnerable population. Blood samples were collected from
neonates treated with ciprofloxacin and concentrations were quantified by high-pressure liquid chromatography–mass spectrometry. Population pharmacokinetic analysis was performed using NONMEM software. The data from 60 newborn infants
(postmenstrual age [PMA] range, 24.9 to 47.9 weeks) were available for population pharmacokinetic analysis. A two-compartment model with first-order elimination showed the best fit with the data. A covariate analysis identified that gestational age,
postnatal age, current weight, serum creatinine concentration, and use of inotropes had a significant impact on ciprofloxacin
pharmacokinetics. Monte Carlo simulation demonstrated that 90% of hypothetical newborns with a PMA of <34 weeks treated
with 7.5 mg/kg twice daily and 84% of newborns with a PMA >34 weeks and young infants receiving 12.5 mg/kg twice daily
would reach the AUC/MIC target of 125, using the standard EUCAST MIC susceptibility breakpoint of 0.5 mg/liter. The associated risks of overdose for the proposed dosing regimen were <8%. The population pharmacokinetics of ciprofloxacin was evaluated in neonates and young infants <3 months old, and a dosing regimen was established based on simulation.

C

iprofloxacin, a synthetic fluoroquinolone, can be used to treat
sepsis caused by multiple resistant organisms (1). It is not
considered a first-line treatment in current guidelines for neonatal
sepsis but is used in severe infections caused by Enterobacter spp.
resistant to standard treatment and when there is a major risk of
meningitis and secondary cerebral abscess (2, 3). In a recent European survey, ciprofloxacin was used “off-label” in 25% of neonatal
intensive care units, mainly in cases of culture-proven bacterial sepsis
due to multidrug-resistant organisms that are sensitive to ciprofloxacin (4).
After intravenous administration, ciprofloxacin is widely distributed in most bodily fluids and tissues, with a high penetration in the
cerebrospinal fluid (CSF) and central nervous system. Glomerular
filtration and tubular secretion are the main mechanisms of renal
excretion, and ⬎65% of ciprofloxacin is excreted unchanged by the
kidney (5). In adults, the area under the concentration-time curve
from 0 to 24 h (AUC0⫺24)/MIC ratio appears to be the best predictor
of microbiological and clinical outcome. A target AUC0⫺24/MIC
value of 125 was required for treating Gram-negative infections (6, 7).
Since data in neonates are limited, the present study was conducted to assess the population pharmacokinetics of ciprofloxacin in
neonates and young infants ⬍3 months of age and to use these data to
calculate an optimal dosing regimen of ciprofloxacin for use in these
patients.
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MATERIALS AND METHODS
Study design. The trial was a prospective, open label pharmacokinetic
study of ciprofloxacin, conducted in the neonatal intensive care unit of the
Liverpool women’s hospital and in the pediatric intensive care unit of the
Alder Hey Children’s Hospital, Liverpool, United Kingdom. Inclusion
and exclusion criteria are presented in Fig. 1. The study was approved by
the institutional ethics board and independent ethics board of the TINN
project (EudraCT 2010-019955-23). It was also monitored by an independent safety monitoring board (DSMB).
Dosing regimen and pharmacokinetic sampling. Ciprofloxacin (generic; Peckforton Pharmaceuticals, Crewe, United Kingdom) was administered as an intravenous infusion either over either 30 or 60 min by using
a syringe pump connected to microbore tubing at a dose of 10 mg/kg/dose
twice daily (BID) for neonates with a postmenstrual age (PMA) of ⬍40
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FIG 1 Inclusion and exclusion criteria.

weeks and three times daily (TID) or BID for young infants with a PMA of
ⱖ40 weeks.
Ciprofloxacin pharmacokinetics was assessed on day 1 (D1) or D2 of
treatment and again between D5 and D7. The total number of studyspecific blood samples was restricted to six per participant with a maximum of three on each sampling day. Patients were randomly assigned to
one of the two predefined three-time point schedules (Table 1). Precise
infusion and sample times were recorded. The blood volume of samples
obtained for pharmacokinetic analyses was 0.2 ml per sample. Scavenged
samples were also obtained from blood remaining after routine biochemical tests. Only samples with validated sampling information were included. Blood samples were refrigerated and centrifuged (2,500 ⫻ g at 4C
for 10 min), and serum or plasma was stored at ⫺70°C. Samples were
shipped on dry ice to the Department of Pediatric Pharmacology at Robert
Debré Hospital, where they were stored at ⫺70°C prior to analysis.
Analytical method of ciprofloxacin and creatinine. The analytical
method of ciprofloxacin has been reported previously (8). Briefly, ciprofloxacin concentrations were determined using high-performance liquid
chromatography with mass spectrometry with ciprofloxacin-d8 as an internal standard. The calibration curve ranged from 25 to 3,000 ng/ml. The
inter- and intraday coefficients of variation of controls were 4.1 and 2.4%,
respectively. The lower limit of quantification was 25 ng/ml. Serum creatinine concentrations were measured by an adapted Jaffé method using
the Architect C system (Abbott Diagnostics, Abbott Park, IL).
Population pharmacokinetic modeling of ciprofloxacin. Pharmacokinetic analysis was carried out using the nonlinear mixed effects model-

TABLE 1 Pharmacokinetic sampling schedule
Group
Ciprofloxacin administered
twice daily
A
B
Ciprofloxacin administered
three times daily
C
D

Sampling timea

End of infusion*

T3
T2

End of infusion*

T8
T6

T12

T4

T8
T8

T3
T2

a
The sampling times are indicated with reference to the start of ciprofloxacin infusion.
*, For infants weighing ⬍1,000 g, samples were taken randomly on two specific times to
minimize blood loss and to ensure representation of each period.
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ing program NONMEM v7.2 (Icon Development Solutions, San Antonio,
TX). First-order conditional estimation method with interaction was used
to estimate pharmacokinetic parameters and their variability.
The interindividual variability of the pharmacokinetic parameters was
estimated by using an exponential model and was expressed as follows:
i ⫽ mean*ei, where i represents the parameter value of the ith subject,
mean is the typical value of the parameter in the population, and i is the
variability between subjects, which is assumed to follow a normal distribution with a mean of zero and variance 2.
Covariate analysis followed a forward and backward selection process.
The likelihood ratio test was used to test the effect of each variable on
model parameters. The effects of current weight, birth weight, gestational
age, postnatal age, postmenstrual age, serum creatinine concentration
(collected within ⱕ48 h of pharmacokinetic sampling), and comedication
were investigated as potential variables affecting pharmacokinetic parameters. During the first step of covariate model building, a covariate was
included if a significant (P ⬍ 0.05, 2 distribution with one degree of
freedom) decrease (reduction ⬎ 3.84) in the objective function value
(OFV) from the basic model and a reduction in the variability of the
pharmacokinetic parameter were obtained. All of the significant covariates were then added simultaneously into a “full” model. Subsequently,
each covariate was independently removed from the full model. If the
increase in the OFV was higher than 6.635 (P ⬍ 0.01, 2 distribution), the
covariate was considered significantly correlated with the pharmacokinetic parameter and was therefore retained in the final model.
Model validation was based on graphical and statistical criteria. Goodness-of-fit plots, including observed (DV) versus population prediction
(PRED), DV versus individual prediction (IPRED), conditional weighted
residuals (CWRES) versus time, and CWRES versus PRED, were initially
used for diagnostic purposes (9). The stability and performance of the
final model was also assessed by means of a nonparametric bootstrap with
resampling and replacement. Resampling was repeated 500 times, and the
values of estimated parameters from the bootstrap procedure were compared to those estimated from the original data set. The entire procedure
was performed in an automated fashion, using PsN (v2.30) (10). The final
model was also evaluated graphically and statistically by normalized prediction distribution errors (NPDE) and prediction-corrected visual predictive check (pcVPC) (11, 12). One-thousand data sets were simulated
using the final population model parameters. The NPDE results were
summarized graphically by default as provided by the NPDE R package
(v1.2) (13): (i) QQ-plot of the NPDE and (ii) histogram of the NPDE. The
NPDE is expected to follow an “N(0,1)” distribution. For pcVPC, ob-

aac.asm.org 6573

Zhao et al.

TABLE 2 Baseline characteristics in 60 neonates and infants
Characteristicsa
Total patients
Gender (male/female)
Race (Caucasian/Asian/
unknown)
IUGR
GA (wks)
PMA (wks)
PNA (days)
Birth wt (g)
Current wt (g)
Serum creatinine concn
(mol/liter)

FIG 2 Trial flow chart.

served and simulated dependent variables were normalized based on the
typical population prediction for the median independent variable in the
bin. The 95% confidence intervals for the median and the 5th and 95th
percentiles of the prediction-corrected simulated concentrations were
calculated, plotted against the time, and compared to the prediction-corrected observed concentrations.
Ciprofloxacin penetration into the CSF. Assessment of the ciprofloxacin penetration into the CSF was evaluated by the CSF/serum ciprofloxacin concentration ratio. Because serum ciprofloxacin concentrations
were not obtained concurrently with CSF sample collection, serum concentrations at the time of CSF sample collection were calculated via Bayesian estimation using the final model.
Dosing regimen optimization. Monte Carlo simulations were performed using the parameter estimates obtained from the final model in
order to define optimal dosing regimen able to attain the target AUC/MIC
value of 125 h in ca. 80% of patients. To ensure comparable safety profiles,
the percentage of patients below the reported maximum AUC was also
considered. The pediatric dose of ciprofloxacin was simulated on a mg/kg
basis according to different age groups. Thus, various mg/kg dosing regimens (5, 7.5, 10, 12.5, and 15 mg/kg/dose BID) were simulated in each
neonatal group. One-thousand simulations were performed using the
original data set, and AUC0⫺24 at steady state was calculated for each
simulated patient. The target attainment rate was then calculated for each
dosing regimen to define the optimal dose regimen in each neonatal
group.

RESULTS

Study population. Sixty-four patients were initially included
from February 2011 to June 2012. All of the patients fulfilled the
inclusion and exclusion criteria, and informed consent was obtained from all patients. Four patients were excluded from the
pharmacokinetic analysis for the following reasons: two patients
were withdrawn from the study, one patient was treated with dialysis, and one patient received ciprofloxacin within 36 h of inclusion. Finally, 60 newborns were included for the population pharmacokinetic analysis. Of these, 7 received ciprofloxacin at 5 mg/
kg/dose BID, 6 were administered ciprofloxacin at 10 mg/kg/dose
TID, and 47 were given ciprofloxacin at 10 mg/kg/dose BID. No
patients discontinued the ciprofloxacin treatment due to adverse
events, and no drug-related adverse events were shown to have a
causal association with ciprofloxacin therapy. The trial flow is presented in Fig. 2.
The mean ⫾ the standard deviation postmenstrual age (PMA)
and weight of the 60 patients at the time of study were 35.7 ⫾ 6.5
weeks (range, 24.9 to 47.9) and 2,060 ⫾ 1,020 g (range, 700 to
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No. of
patients

Median (range)

30.4 (5.8)
35.7 (6.5)
38 (30)
1,518 (884)
2,060 (1020)
52 (32)

27.9 (23.3–42.0)
36.5 (24.9–47.9)
27 (5–121)
1,115 (540–3850)
1,955 (700–4200)
41 (22–164)

5 (4)
18.9 (10.1)
9.1 (1.6)

5 (1–17)
18.7 (4.5–40.0)
9.7 (4.4–11.0)

3

Ciprofloxacin treatment
Duration (days)
Dose (mg/dose)
Dose (mg/kg/dose)
Comedication
Inotropic agents
Teicoplanin
Diuretics
Caffeine
Amoxicillin-clavulanic acid
Nystatin
Colistin-tobramycinamphotericin B

Mean (SD)

60
39/21
53/5/2

22
41
30
15
12
12
10

a
IUGR, intrauterine growth restriction; GA, gestational age at birth; PMA,
postmenstrual age; PNA, postnatal age.

4,200 g), respectively. The PMA and current weight were all normally distributed (P ⫽ 0.4 and P ⫽ 0.2, respectively [KolmogorovSmirnov test]). A summary of patient characteristics is presented
in Table 2.
Model building. For population modeling, 430 ciprofloxacin
concentrations (265 pharmacokinetic and 165 scavenged samples) were available. The ciprofloxacin concentrations of pharmacokinetic and scavenged samples ranged from 450 to 15,976 and
from 52 to 10,961 ng/ml, respectively. The concentration versus
time profile is shown in Fig. 3.
A two-compartment model with first-order elimination fitted
the data. The OFV value and residual variability of the two-compartment model were lower than those of the one-compartment

FIG 3 Ciprofloxacin concentrations versus time. The solid line represents the
population prediction of a typical patient.
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TABLE 3 Covariate analysis
Characteristica
Structural model
Allometric model
Current body wt

Pharmacokinetic
parameter(s)

IIVb CL
(%)

6,569.0c

98.3

6,455.1

67.6

CL, V1, V2, Q

Impact of age
GA
PNA
PMA

V1

Impact of age
GA
PNA
PMA

V2

Impact of renal maturation
Birth wt
GA
PNA
PMA
Birth wt and PNA

CL

GA and PNA
Impact of renal function
Serum creatinine

Objective function
value

6,454.9
6,451.9
6,453.2

6,455.1
6,452.3
6,453.7

6,442.0
6,438.7
6,425.2
6,399.5
6,396.2
6,388.4

43.6

42.5

CL
6,429.3

Impacts of renal maturation and renal function
GA, PNA, and serum creatinine

CL

Impacts of renal maturation, renal function, and comedication
GA, PNA, serum creatinine, and diuretics
GA, PNA, serum creatinine, and caffeine
GA, PNA, serum creatinine, and teicoplanin
GA, PNA, serum creatinine, and amoxicillin-clavulanic acid
GA, PNA, serum creatinine, and nystatin
GA, PNA, serum creatinine, and inotropic agents

CL

6,371.3

36.9

6,371.4
6,369.2
6,371.0
6,366.8
6,370.9
6,363.8

34.5

a

GA, gestational age; PNA, postnatal age; PMA, postmenstrual age.
b
IIV, interindividual variability.
c
OFV values of model with significant improvement are indicated in boldface.

model. The model was parameterized in terms of the central volume of distribution (V1), the peripheral volume of distribution
(V2), the intercompartment clearance (Q), and the clearance (CL)
of ciprofloxacin. Interindividual variability was best described by
an exponential model and was then estimated for V1, V2, and CL.
Interoccasion variability on CL was coupled to interindividual
variability by an additive model, respectively. A proportional
model best described residual variability.
Covariate analysis. The allometric size approach was used by
incorporating a priori the current weight into the basic model
(allometric coefficients of 0.75 for CL and Q and of 1 for V1 and
V2), which caused a significant drop in the OFV of 113.9 points.
Postmenstrual age was identified as the most important covariate
on CL, associated with a drop in the OFV of 55.6 U. However,
gestational age and postnatal age together proved to be superior
(⌬OFV 66.7 U) to postmenstrual age alone. A further decrease in
the OFV of 17.1 U was achieved by implementing the serum creatinine concentration on clearance. The model was further improved by introducing the coadministration of inotropic agents
(⌬OFV 7.5 U) as a third covariate on clearance. For V1, only the
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coadministration of inotropic agents caused a significant drop in
the OFV of 3.9 points in the forward selection process. However, it
was not retained in the model after the backward selection process. A detailed presentation of the covariate analysis results is
presented in Table 3. Size explained 31.2%, renal maturation explained 25.6%, renal function explained 5.7%, and coadministration of inotropic agents explained 2.4% of the ciprofloxacin CL
variability. The  shrinkages were 5.4% for CL, 25.7% for V1, and
25.0% for V2, respectively. The ε shrinkage was 13.6%.
Table 4 summarizes parameter estimates of the final pharmacokinetic model. The median (range) of estimated weight-normalized CL
and volume distribution at steady state (sum of V1 and V2) were 0.20
(0.04 to 0.81) liters/h/kg and 2.02 (0.40 to 3.55) liters/kg, respectively.
The AUC0⫺24 at steady state for the evaluated dose regimen ranged
from 35 to 291 mg·h/liter. Ciprofloxacin CL increased allometrically
with current weight in neonates and young infants, decreased with
increasing creatinine concentration, and showed a 29% decrease with
the coadministration of inotropic agents. The relationship between
ciprofloxacin weight-normalized CL (liters/kg) versus postmenstrual
age is shown in Fig. 4.

aac.asm.org 6575
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TABLE 4 Population pharmacokinetic parameters of ciprofloxacin and bootstrap results
Full data set
a

Bootstrap

Parameter

Final estimate

RSE (%)

Median

5th–95th percentile

V1 (liters)
V1 ⫽ 1 ⫻ (CW/1955)
1

1.97

17.7

1.82

0.78–2.59

V2 (liters)
V2 ⫽ 2 ⫻ (CW/1955)
2

1.93

21.9

1.97

1.38–3.02

Q (liters/h)
Q ⫽ 3 ⫻ (CW/1955)0.75
3

2.5

32.6

2.62

1.02–5.41

CL (liters/h)
CL ⫽ 4 ⫻ (CW/1955)0.75 ⫻ Fage ⫻ RF ⫻ Finotrope
4

0.366

6.0

0.365

0.323–0.407

Fage ⫽ (GA/27.9)5 ⫻ (PNA/27)6
5
6

2.11
0.494

11.9
10.8

2.09
0.492

1.60–2.57
0.386–0.606

RF ⫽ EXP[(CREA-42) ⫻ 7]
7

⫺0.00335

46.0

⫺0.00331

⫺0.00753 to ⫺0.00063

Finotrope
8

0.708

10.9

0.719

0.572–0.869

Interindividual variability (%)
V1
V2
CL

48.1
49.3
33.2

63.6
68.3
19.9

49.6
51.2
31.3

26.2–77.2
15.8–76.9
25.3–37.4

Interoccasion variability (%)
CL

16.4

55.6

16.6

9.2–26.2

Residual variability (%)

19.3

28.2

18.7

14.8–23.1

a

V1, central volume of distribution; V2, peripheral volume of distribution; Q, intercompartment clearance; CL, clearance; RF, renal function; CW, current weight in grams;
Finotrope, scaling factor applied for patients coadministered with inotropic agents; CREA, serum creatinine concentration in mol/liter; GA, gestational age in weeks; PNA, postnatal
age in days. In our population, 1,955 g, 27.9 weeks, 27 days, and 42 mol/liter were the median current weight (at the day of the study), gestational age, postnatal age, and serum
creatinine concentration values, respectively.

Model evaluation. Model diagnostics showed acceptable goodness-of-fit for the final model of ciprofloxacin. As shown in Fig. 5A
and B, the predictions are unbiased. In the diagnostic plots of
CWRES versus time and PRED, no trends were observed (Fig. 5C
and D). In addition, the median parameter estimates resulting
from the bootstrap procedure closely agreed with the respective
values from the final population model, indicating that the final
model is stable and can redetermine the estimates of population
pharmacokinetic parameters (Table 4). The NPDEs are presented
in Fig. 5E and F. NPDE distribution and histogram met well the
theoretical N(0,1) distribution and density, indicating a good fit of
the model to the individual data. The mean and variance of the
NPDE were 0.05 (Wilcoxon signed-rank test, P ⫽ 0.19) and 0.91
(Fisher variance test, 0.17), respectively. The pcVPC is shown in
Fig. 5G. The prediction-corrected observed concentrations fit well
the simulated concentrations, confirming the predictive performance of the developed model.
Ciprofloxacin penetration into the CSF. The concentrations of ciprofloxacin in six CSF samples ranged from 187 to
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1,650 ng/ml, respectively. The median value of CSF/serum
concentration ratio was 0.32 (range, 0.08 to 0.58). A trend for
correlation between the CSF collection time and the CSF/
serum concentration ratios was demonstrated, suggesting less
elimination from (or diffusion in) the CSF than the systemic
circulation (Fig. 6).
Dosing regimen optimization. The target attainment rates as a
function of dose and age groups for a standard MIC susceptibility
breakpoint of 0.5 mg/liter are shown in Fig. 7. A cutoff point of a
PMA of 34 weeks was selected to separate age groups based on
visual inspection of the plot showing CL versus PMA (Fig. 4).
A total of 90% of simulated newborns with a PMA of ⬍34
weeks and 84% of newborns with a PMA of ⱖ34 weeks achieved
the target AUC/MIC values of 125 h when treated at doses of 7.5
and 12.5 mg/kg BID, respectively. The associated risks of overdose
(AUC ⬎ 291 mg·h/liter, the maximal value reported in the present
study, did not show short-term adverse events) for the proposed
dosing regimen were ⬍8%. Higher doses will be required for patients with more resistant bacterial strains.

Antimicrobial Agents and Chemotherapy
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FIG 4 Ciprofloxacin CL versus PMA.

DISCUSSION

This is the first population pharmacokinetic study of ciprofloxacin conducted in a cohort of neonates and young infants. It was
undertaken to estimate ciprofloxacin pharmacokinetic parameters and to evaluate the impact of demographic, clinical, and biological factors on ciprofloxacin disposition. Our results show that
a two-compartment model with first-order elimination with gestational age, postnatal age, current weight, serum creatinine concentration, and coadministration of inotropic agents was optimal
for data modeling.
Ciprofloxacin is a fluoroquinolone targeting bacterial DNA
gyrase enzyme, a member of the class of type II topoisomerases
that displays in vitro activity against most Gram-negative and
many Gram-positive pathogenic bacteria, many of which are resistant to a wide range of antibiotics. Ciprofloxacin has a complex
safety profile. A range of adverse drug reactions, including arthropathies, without identified long-term effects, need to be balanced with its efficacy (14–16). Potential neuroprotective effects
were demonstrated in a juvenile animal model subjected to Escherichia coli sepsis (17). Increase in multidrug-resistant sepsis
forces the use of ciprofloxacin (18, 19). However, dosages vary
widely from one country to another and from one center to another within the same country (4), since only a few pharmacokinetic studies have been conducted in preterm and term neonates
(20–22). Since ciprofloxacin is mainly eliminated by the renal
route, renal anatomical and functional maturation is expected to
have a major influence on ciprofloxacin clearance and dosing in
neonates and young infants. When the current weight is taken into
account using an allometric scaling approach, the independent
impact of gestational and postnatal ages on clearance illustrates
the influence of both antenatal and postnatal renal maturation on
ciprofloxacin clearance (Fig. 8); this includes the expected consequences of the normal pattern of renal function ontogeny (23).
Renal function, as reflected by serum creatinine concentrations, was significantly and independently correlated with ciprofloxacin clearance in the present study. The relation of serum creatinine to the glomerular filtration rate (GFR) at birth is
complicated. There was no unique equation to describe the relationship between renal function and drug clearance in neonates.
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We have demonstrated that the variation in the serum creatinine
measurement had a considerable impact on the transferability of a
published creatinine-based dosing regimen of renal excreted drug
to different clinical settings (24). The influence of residual maternally derived creatinine seems to be limited in our study, since
neonates at ⱖ5 days of age were included. Ciprofloxacin clearance
decreased with the coadministration of inotropic drugs. A possible explanation is that inotropic agents are often given when there
is decreased blood pressure, which will result in decreased GFR.
The same effect was observed by Seay et al. (25), who reported that
the coadministration of dopamine induced a 28% decrease in vancomycin clearance in neonates. The use of inotropic agents may be
also a surrogate for underlying hemodynamic instability and altered renal hemodynamics, resulting in decreased drug elimination, as suggested by previous investigators (25). We were unable
to demonstrate any significant effect of ventilation or intrauterine
growth retardation on ciprofloxacin disposition. Clearly, the impact of these variables on ciprofloxacin neonatal pharmacokinetics is complex, probably even more in critically ill neonates. In
addition, our study is probably not able to demonstrate their full
impact.
In adults, the best surrogate for the ciprofloxacin pharmacokinetic-pharmacodynamic relationship is the AUC0⫺24/MIC ratio.
A target AUC0⫺24/MIC value of 125 h was required against Gramnegative infections (6, 7). According to regulatory guidelines (26–
28), the pharmacokinetic-pharmacodynamic relationship for most
anti-infective drugs can be assumed to be similar across all age
groups, including neonates, making ciprofloxacin a good example for
demonstrating that modeling and simulation approaches can be used
to establish optimal dosage recommendations in neonates. Dosage
administration in neonates is commonly based on an mg/kg basis
according to the different age groups (preterm or term neonates), and
a standard mg/kg dose is calculated accordingly in each group. In the
present study and in order to reach “optimal but practical dosage
recommendations” for clinicians, two groups of patients were defined, newborns with a PMA of ⬍34 weeks or a PMA of ⱖ34 weeks,
and the dose required to achieve the predefined AUC/MIC target was
adapted to body weight (i.e., in mg/kg) in the two age groups. The
simulation approach demonstrates that doses of 7.5 mg/kg for new-
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FIG 5 Model evaluation for ciprofloxacin. (A) Population predicted (PRED) versus observed concentrations (DV); (B) individual predicted (IPRED) versus DV; (C)
conditional weighted residuals (CWRES) versus time; (D) CWRES) versus PRED; (E) QQ-plot of the distribution of the normalized prediction distribution errors
(NPDE) versus the theoretical N(0,1) distribution; (F) histogram of the distribution of the NPDE, with the density of the standard Gaussian distribution overlaid; (G)
prediction-corrected visual predictive check. The circles represent the prediction-corrected observed concentrations. The solid line represent the median predictioncorrected observed concentrations and semitransparent gray field represents simulation-based 95% confidence intervals for the median. The observed 5th and 95th
percentiles are indicated by dashed lines, and the 95% intervals for the model-predicted percentiles are indicated as corresponding semitransparent gray fields.
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FIG 6 Ciprofloxacin CSF/serum concentration ratio versus time.

borns with a PMA of ⬍34 weeks and 12.5 mg/kg for newborns with a
PMA of ⱖ34 weeks given twice daily allowed 90 and 84% of the
patients, respectively, to achieve the AUC/MIC target, with a standard EUCAST MIC susceptibility breakpoint of 0.5 mg/liter (29). For
this optimal dosing regimen, the associated risks of overdose, which
was defined as the simulated AUC over the maximum reported value
of 291 mg·h/liter, were low (⬍8%), which supports a balanced effi-

FIG 8 Model-based predicted impact of renal maturation on the clearance of
ciprofloxacin in neonates. The influence of both gestational age (GA; representing antenatal maturation) and postnatal age (PNA; representing postnatal
maturation) on renal maturation is depicted graphically.

cacy and safety profile associated with the recommended dosing regimens. Clearly, organisms with a higher MIC would require a higher
AUC to achieve the same outcome (6, 30). In the United States, the
Clinical Laboratory Standards Institute’s breakpoint is even higher
with a, MIC of ⬎1 mg/liter (31) and, as a consequence, a double dose
(with assumption of linear pharmacokinetics) would be required to
achieve the same AUC/MIC target.
The pharmacokinetic model of ciprofloxacin was developed
and internally validated. External validation was not performed
because of the limited number of patients currently exposed to
this drug. Ultimately, a patient-tailored dose based on modeling
and simulation has to be evaluated in clinical practice to confirm
its clinical benefits.
Conclusion. A population pharmacokinetic model of ciprofloxacin was developed in neonates and young infants, showing a
low clearance of the drug, compared to older children and adults.
Gestational age at birth, postnatal age, current weight, serum creatinine concentration, and the coadministration of inotropic
agents had significant impact on ciprofloxacin pharmacokinetics.
The ciprofloxacin dosing regimen in neonates and young infants
⬍3 months old was established based on population pharmacokinetics analysis.
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Overdose is defined as an AUC over the maximum reported value of 291
mg·h/liter.

November 2014 Volume 58 Number 11

We thank all the children and their families for participating in this study.
This work is part of the TINN network (Collaborative Project) supported
by the European Commission under the Health Cooperation Work Program of the 7th Framework Program (grant agreement 223614). We acknowledge the UK National Institute for Health Research for supporting
the delivery of the trial and the clinical teams at the Liverpool Women’s
NHS FT and Alder Hey Children’s NHS FT Liverpool UK.
E.J.A., C.L.G., B.K., J.N.V.D.A., and M.A.T. designed the study; all
authors contributed to the final version of the protocol; H.H., W.Z.,
C.L.G., and E.J.-A. developed the eCRF, H.H. designed S.P., H.H., T.N.,
S.M., S.P., and M.A.T. organized the trial and recruited patients; W.Z. and
E.J.-A. set up the analytical method; W.Z., C.L.G., and E.J.-A. performed
the population pharmacokinetic analysis; W.Z. and E.J.-A. drafted the
first version of the manuscript; significant contributions to the final version were provided by C.L.G., J.N.V.D.A., and G.L.K.
The TINN consortium includes the following individuals: Wei Zhao,
Boris Matrot, Jorge Gallego, and Evelyne Jacqz-Aigrain, French National
Institute of Health and Medical Research; Helen Hill, Tim Neal, Tony
Nunn, and Mark Turner, University of Liverpool; Helen Sammons and

aac.asm.org 6579

Zhao et al.

Imti Choonara, University of Nottingham; Natacha Edme and Jerome
Weinbach, INSERM-Transfert; Charlotte Castellan, Kim-An Nguyen,
and Behrouz Kassai, Claude Bernard University Lyon 1; Paolo Manzoni,
Sant’Anna Hospital; John Van Den Anker and Rene Kornelisse,
ERASMUS-Medical Center; Julia Stingl, University of Ulm; Jean-Paul
Langhendries, Centre Hospitalier Chrétien; Bart Van Overmeire, University of Antwerp; Chantal Le Guellec, François Rabelais University; Valérie
Biran, May Fakhoury, Florentia Kaguelidou, Pierre-Henri Jarreau, and
Corinne Alberti, Assistance Publique-Hôpitaux de Paris; Patrick Chevarier, Clininfo SA; Chiara Pandolfini and Maurizio Bonati, Istituto di
Ricerche Farmacologiche Mario Negri; and Anders Rane, Karolinska Institute.

16.

17.

18.

REFERENCES
1. Gendrel D, Chalumeau M, Moulin F, Raymond J. 2003. Fluoroquinolones
in paediatrics: a risk for the patient or for the community? Lancet Infect. Dis.
3:537–546. http://dx.doi.org/10.1016/S1473-3099(03)00736-9.
2. Gray JW, Patel M. 2011. Management of antibiotic-resistant infection in
the newborn. Arch. Dis. Child. Educ. Pract. Ed. 96:122–127. http://dx.doi
.org/10.1136/adc.2010.199653.
3. Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E. 2011. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr. Infect. Dis. J.
30:e29 – e37. http://dx.doi.org/10.1097/INF.0b013e3181fe353d.
4. Pandolfini C, Kaguelidou F, Sequi M, Jacqz-Aigrain E, Choonara I,
Turner MA, Manzoni P, Bonati M. 2013. Wide intra- and inter-country
variability in drug use and dosage in very-low-birth-weight newborns
with severe infections. Eur. J. Clin. Pharmacol. 69:1031–1036. http://dx
.doi.org/10.1007/s00228-012-1415-2.
5. Vance-Bryan K, Guay DR, Rotschafer JC. 1990. Clinical pharmacokinetics of ciprofloxacin. Clin. Pharmacokinet. 19:434 – 461. http://dx.doi
.org/10.2165/00003088-199019060-00003.
6. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ.
1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073–1081. http://dx.doi.org
/10.1128/AAC.37.5.1073.
7. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY,
Schouten MA, Girbes AR. 2008. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J. Crit. Care 23:422– 430.
http://dx.doi.org/10.1016/j.jcrc.2007.11.011.
8. Grondin C, Zhao W, Fakhoury M, Jacqz-Aigrain E. 2011. Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass
spectrometry: an adapted method for neonates. Biomed. Chromatogr.
25:827– 832. http://dx.doi.org/10.1002/bmc.1523.
9. Hooker AC, Staatz CE, Karlsson MO. 2007. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res.
24:2187–2197. http://dx.doi.org/10.1007/s11095-007-9361-x.
10. Lindbom L, Ribbing J, Jonsson EN. 2004. Perl-speaks-NONMEM (PsN):
a Perl module for NONMEM related programming. Comput. Methods
Programs. Biomed. 75:85–94. http://dx.doi.org/10.1016/j.cmpb.2003.11
.003.
11. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. 2006. Metrics for
external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 23:2036 –2049. http://dx.doi.org/10
.1007/s11095-006-9067-5.
12. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects
modes. AAPS J. 13:143–151. http://dx.doi.org/10.1208/s12248-011-9255-z.
13. Comets E, Brendel K, Mentré F. 2008. Computing normalised prediction
distribution errors to evaluate nonlinear mixed-effect models: the npde
add-on package for R. Comput. Methods Programs Biomed. 90:154 –166.
http://dx.doi.org/10.1016/j.cmpb.2007.12.002.
14. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. 2011. Ciprofloxacin safety in paediatrics: a systematic review. Arch. Dis. Child. 96:
874 – 880. http://dx.doi.org/10.1136/adc.2010.208843.
15. Sendzik J, Lode H, Stahlmann R. 2009. Quinolone-induced arthropathy:
an update focusing on new mechanistic and clinical data. Int. J. Antimi-

6580

aac.asm.org

19.

20.
21.

22.

23.

24.

25.
26.

27.

28.

29.
30.

31.

crob. Agents 33:194 –200. http://dx.doi.org/10.1016/j.ijantimicag.2008.08
.004.
Drossou-Agakidou V, Roilides E, Papakyriakidou-Koliouska P, Agakidis C, Nikolaides N, Sarafidis K, Kremenopoulos G. 2004. Use of
ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year.
Pediatr. Infect. Dis. J. 23:346 –349. http://dx.doi.org/10.1097/00006454
-200404000-00014.
Loron G, Olivier P, See H, Le Saché N, Angulo L, Biran V, Brunelle N,
Besson-Lescure B, Kitzis MD, Pansiot J, Bingen E, Gressens P, Bonacorsi S, Baud O. 2011. Ciprofloxacin prevents myelination delay in neonatal rats subjected to Escherichia coli sepsis. Ann. Neurol. 69:341–351.
http://dx.doi.org/10.1002/ana.22190.
Shane AL, Stoll BJ. 2013. Recent developments and current issues in the
epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. Am. J. Perinatol. 30:131–142. http://dx.doi.org/10.1055/s-0032
-1333413.
Hornik CP, Fort P, Clark RH, Watt K, Benjamin DK, Jr, Smith PB,
Manzoni P, Jacqz-Aigrain E, Kaguelidou F, Cohen-Wolkowiez M. 2012.
Early and late onset sepsis in very-low-birth-weight infants from a large
group of neonatal intensive care units. Early. Hum. Dev. 88:S69 –S74. http:
//dx.doi.org/10.1016/S0378-3782(12)70019-1.
Aggarwal P, Dutta S, Garg SK, Narang A. 2004. Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. Indian Pediatr. 41:1001–
1007.
Peltola H, Väärälä M, Renkonen OV, Neuvonen PJ. 1992. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children.
Antimicrob. Agents Chemother. 36:1086 –1090. http://dx.doi.org/10
.1128/AAC.36.5.1086.
van den Oever HL, Versteegh FG, Thewessen EA, van den Anker JN,
Mouton JW, Neijens HJ. 1998. Ciprofloxacin in preterm neonates: case
report and review of the literature. Eur. J. Pediatr. 157:843– 845. http://dx
.doi.org/10.1007/s004310050949.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS,
Kauffman RE. 2003. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157–1167.
http://dx.doi.org/10.1056/NEJMra035092.
Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV,
Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN,
Fakhoury M, Jacqz-Aigrain E. 2013. External evaluation of population
pharmacokinetic models of vancomycin in neonates: the transferability of
published models to different clinical settings. Br. J. Clin. Pharmacol. 75:
1068 –1080. http://dx.doi.org/10.1111/j.1365-2125.2012.04406.x.
Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. 1994.
Population pharmacokinetics of vancomycin in neonates. Clin. Pharmacol. Ther. 56:169 –175. http://dx.doi.org/10.1038/clpt.1994.120.
Food and Drug Administration. 2014. Guidance for industry—
exposure-response relationships: study design, data analysis, and regulatory applications. U.S. Food and Drug Administration, Washington, DC.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/ucm072109.pdf.
European Medicines Agency. 2014. Guideline on evaluation of medicinal
products indicated for treatment of bacterial infections (CPMP/EWP/558/95
rev2). European Medicines Agency, London, United Kingdom. http://www
.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009
/09/WC500003417.pdf.
European Medicines Agency. 2014. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. Document CPMP/EWP/2655/99. European Medicines
Agency, London, United Kingdom.
EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone
diameters, version 4.0. EUCAST, Växjö, Sweden.
Lipman J, Gous AG, Mathivha LR, Tshukutsoane S, Scribante J, Hon H,
Pinder M, Riera-Fanego JF, Verhoef L, Stass H. 2002. Ciprofloxacin
pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin
is enough? Intensive Care Med. 28:493–500. http://dx.doi.org/10.1007
/s00134-002-1212-y.
CLSI. 2011. Standards for antimicrobial susceptibility testing. CLSI,
Wayne, PA.

Antimicrobial Agents and Chemotherapy

